STUDY ON TREATMENT OUTCOMES AND TOXICITY OF ORAL VINORELBINE MONOTHERAPY IN PATIENTS WITH RECURRENT AND METASTATIC BREAST CANCER
Main Article Content
Abstract
Background: Breast cancer is one of the most prevalent cancers in women. The use of oral vinorelbine monotherapy in the treatment of recurrent and metastatic breast cancer has not been extensively studied in Vietnam. Objective: To evaluate the treatment efficacy and toxicity of oral vinorelbine monotherapy in patients with recurrent and metastatic breast cancer. Material and methods: A descriptive case series study was conducted on 23 patients diagnosed with recurrent/metastatic breast cancer confirmed through pathological and imaging diagnoses. These patients received oral vinorelbine monotherapy at the Oncology Center - Cho Ray Hospital from January to December, 2021. Results: The average treatment duration was 4.7 months. The disease stabilization rate after 3 months was 52.2%, with partial response at 13% and complete response at 4.3%. The disease stabilization rate after 6 months was 40%. Partial or complete response was observed in 17.3% of patients after 3 months. Disease stabilization was noted in 52.2% of patients, while 30.5% progressed. After 6 months of treatment, 60% of patients progressed. The median progression-free survival time was 4.0 months. The progression-free survival rates after 3 and 6 months were 69.6% and 46.6%, respectively. Leukopenia toxicity was observed in 39.1% of patients, with Grade 2 and 3 toxicities at 44.4% and 33.3%, respectively. Elevated liver enzymes occurred in 34.8% of patients, predominantly Grade 1 at 87.5%. Conclusion: Vinorelbine monotherapy regimen demonstrates safe and relatively effective treatment outcomes for recurrent and metastatic breast cancer.
Keywords
Oral vinorelbine, breast cancer recurrence, metastasis
Article Details
References
2. PF Conte1 and S Giovannelli. Oral vinorelbine in metastatic breast cancer: The Vienna experience. Breast Cancer Res. 2005. 7(Suppl 1), S25, doi: 10.1186/bcr1229.
3. Blum J. L. Xeloda in the treatment of metastatic breast cancer. Oncology. 1999. 57 (Suppl 1), 16-20, doi: 10.1159/000055264.
4. Feher O., Vodvarka P., Jassem J. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Annals of Oncology.2005. 16 (6), 899-908, doi: 10.1093/annonc/mdi181.
5. Jones S. E., Erban J.. Overmoyer B. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005. 23 (24), 5542-555, doi:
10.1200/JCO.2005.02.027.
6. O'Brien M. E., Wigler N., Inbar M. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004. 15 (3), 440449, doi: 10.1093/annonc/mdh097.
7. Pajk B., Cufer T., Canney P. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008. 17 (2), 180-185, doi: 10.1016/j.breast.2007.09.002.
8. Piccart-Gebhart M. J., Burzykowski T., Buyse M. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol.2008. 26 (12), 1980-1986, doi: 10.1200/JCO.2007.10.8399.
9. Ranson M. R., Carmichael J., O'Byrne K. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol.1997. 15 (10), 3185-3191, doi: 10.1200/JCO.1997.15.10.3185.
10. Chien-Ting Liu, Meng-Che Hsieh, Yu-Li Su. Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study. J Cancer. 2021. 12(17): 5355–5364, doi: 10.7150/jca.60682.